Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results

Nuclear Medicine and Biology

Volumn 24, Issue 6, 1997, Pages 485-498

  Hom, Roy K ^a   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Neurotransmitter receptor; Neurotransmitter transporter; Steroid receptor

Indexed keywords

CONGO RED; CYSTEINE ETHYL ESTER TC 99M; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; ERGOT ALKALOID; ESTRADIOL; ESTROGEN RECEPTOR; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FURIFOSMIN TC 99M; GLYCOPROTEIN P; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; KETANSERIN; MERTIATIDE TC 99M; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MUSCARINIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; OPIATE ANTAGONIST; PROGESTERONE RECEPTOR; RADIOPHARMACEUTICAL AGENT; RHENIUM COMPLEX; SEROTONIN RECEPTOR; SIGMA OPIATE RECEPTOR; SOMATOSTATIN RECEPTOR; SPIPERONE; TECHNETIUM 99M; TETROFOSMIN TC 99M; TROPANE DERIVATIVE; UNINDEXED DRUG;

COMPLEX FORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ISOTOPE LABELING; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CARRIER PROTEINS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG DESIGN; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SIGMA; RECEPTORS, STEROID; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0030808619     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00066-8     Document Type: Review

References (116)

1. Alkorta I. and Loew G. H. (1996) A 3D model of the δ opioid receptor and ligand-receptor complexes. Protein Eng. 9, 573-583.
2. Amartey J. K. (1993) Technetium-99m labeled somatostatin and analogs: Synthesis, characterization and in vivo evaluation. Nucl. Med. Biol. 20, 539-543.
3. Babich J. W. and Fischman A. J. (1995) Effect of co-ligand on the biodistribution of Tc-99m-labeled hydrazino nicotinic acid derivatized chemotactic peptides. Nucl. Med. Biol. 22, 25-30.
4. Babich J. W., Solomon H., Pike M. C., Kroon D., Graham W., Abrams M. J., et al. (1993) Technetium-99m-labeled hydrazino nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial infection. J. Nucl. Med. 34, 1964-1974.
5. Baidoo K. E., Scheffel U., Lever S. Z., Stathis M. and Wagner H. N., Jr. (1995) Serotonin-1A receptor binding technetium-99m-labeled complexes. J. Nucl. Med. 36, 28P.
6. Ballinger J. R., Bannerman J., Boxen I., Firby P., Hartman N. G. and Moore M. J. (1996) Technetium-99m-Tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J. Nucl. Med. 37, 1578-1582.
7. 99mTc]chelator-peptide conjugates. Bioconjug. Chem. 7, 203-208.
8. Bourguet W., Ruff M., Chambon P., Gronemeyer H. and Moras D. (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-a. Nature 375, 377-382.
9. Buck K. J. and Amara S. G. (1995) Structural domains of catecholamine transporter chimeras involved in selective inhibition by anti-depressants and psychomotor stimulants. Mol. Pharmacol. 48, 1030-1037.
10. Buckman B. O., Bonasera T. A., Kirschbaum K. S., Welch M. J. and Katzenellenbogen J. A. (1995) Fluorine-18-labeled progestin 16α, 17α-dioxolanes: Development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity. J. Med. Chem. 38, 328-337.
11. Chen C-J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M. et al. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381-389.
12. Chen Y.-C. J. and Janda K. D. (1992) A new approach toward the inhibition of ribonucleases: A water-stable ribonucleoside-technetium chelate. J. Am. Chem. Soc. 114, 1488-1489.
13. Chi D. Y. and Katzenellenbogen J. A. (1993) Selective formation of heterodimeric bis-bidentate aminothiol oxometal complexes of rhenium(V). J. Am. Chem. Soc. 115, 7045-7046.
14. Chi D. Y., O'Neil J. P., Anderson C. J., Welch M. J. and Katzenellenbogen J. A. (1994) Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V): Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J. Med. Chem. 37, 928-937.
15. Crankshaw C. L., Marmion M., Burleigh B. D., Deutsch E. and Piwnica-Worms D. (1995) Non-reducible mixed ligand Tc(III) cations (Q complexes) are recognized as transport substrates by the human multidrug-resistance (MDR) P-glycoprotein. J. Nucl. Med. 36, 130P.
16. Crankshaw C. L., Marmion M., Luker G. D., Rao V., Dahlheimer J., Burleigh B. D. et al. (in press) Novel mixed ligand Tc(III) cations (Q-complexes) for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. J. Nucl. Med.
17. de Costa B. R., Radesca L., Di Paolo L. and Bowen W. D. (1992) Synthesis, characterization and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: Structural requirements and binding affinity at the sigma receptors. J. Med. Chem. 35, 38-47.
18. Debonnel G. and de Montigny C. (1996) Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: Possible implications for the treatment of psychiatric disorders. Life Sci. 58, 721-734.
19. 99m/99Tc-DADT-benzovesamicol: A potential marker for cholinergic neurons. Nucl. Med. Biol. 21, 197-203.
20. Dishino D. D., Welch M. J., Kilbourn M. R. and Raichle M. E. (1983) Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J. Nucl. Med. 24, 1030-1038.
21. DiZio J. P., Anderson C. J., Davison A., Ehrhardt G. J., Carlson K. E., Welch M. J. et al. (1992) Technetium-and rhenium-labeled progestins: Synthesis, receptor binding and in vivo distribution of an 11β-substituted progestin labeled with technetium-99 and rhenium-186. J. Nucl. Med. 33, 558-569.
22. DiZio J. P., Fiaschi R., Davison A., Jones A. G. and Katzenellenbogen J. A. (1991) Progestin-rhenium complexes: Metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy. Bioconjug. Chem. 2, 353-366.
23. Eckelman W. C. (1995) Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur. J. Nucl. Med. 22, 249-263.
24. Edvardsen O. and Dahl S. G. (1994) A putative model of the dopamine transporter. Mol. Brain Res. 27, 265-274.
25. Edwards D. S., Cheesman E. H., Watson M. W., Maheu L. J., Nguyen S. A., Dimitre L. et al. (1990) Synthesis and characterization of technetium and rhenium complexes of N,N′-1,2-ethylenediylbis-L-cysteine. Neurolite® and its metabolites. In: Technetium and Rhenium in Chemistry and Nuclear Medicine (Edited by Nicolini M., Bandoli G. and Mazzi U.), Vol. 3, pp. 433-444. Raven Press, New York.
26. Fischman A. J., Babich J. W. and Rubin R. H. (1994) Infection imaging with technetium-99m-labeled chemotactic peptide analogs. Semin. Nucl. Med. 24, 154-168.
27. 3 as a hippuran replacement. J. Nucl. Med. 27, 111-116.
28. Gehlert D. R. (1994) Subtypes of receptors for neuropeptide Y: Implications for the targeting of therapeutics. Life Sci. 55, 551-562.
29. Gronemeyer H. and Laudet V. (1995) Transcription factors 3: Nuclear receptors. In: Protein Profiles (Edited by Sheterline P.), Vol. 2, pp. 1173-1308. Academic Press, London.
30. Han H., Cho C.-G. and Lansbury P. T., Jr. (1996) Technetium complexes for the quantitation of brain amyloid. J. Am. Chem. Soc. 118, 4506-4507.
31. Harris T. D., Rajopadhye M., Damphousse P. R., Glowacka D., Yu K., Bourque J. P. et al. (1996) Tc-99m-labeled fibrinogen receptor antagonists: Design and synthesis of cyclic RGD peptides for the detection of thrombi. Bioorg. Med. Chem. Lett. 6, 1741-1746.
32. Herman L. W., Sharma V., Kronauge J. F., Barbaries E., Herman L. A. and Piwnica-Worms D. (1995) Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J. Med. Chem. 38, 2955-2963.
33. Hom R. K., Chi D. Y. and Katzenellenbogen J. A. (1996) Heterodimeric bis(amino thiol) complexes of oxorhenium(V) that mimic the structure of steroid hormones: Synthesis and stereochemical issues. J. Org. Chem. 61, 2624-2631.
34. Hom R. K. and Katzenellenbogen J. A. (1997) Synthesis of a tetradentate oxorhenium(V) complex mimic of a steroidal estrogen. Manuscript submitted for publication.
35. Horio M., Gottesman M. M. and Pastan I. (1988) ATP-Dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc. Natl. Acad. Sci. USA 85, 3580-3584.
36. Hutchins C. (1994) Three-dimensional models of the D1 and D2 dopamine receptors. Endocrine J. 2, 7-23.
37. Johannsen B., Berger R., Brust P., Pietzsch H.-J., Scheunemenn M., Seifert S. et al. (in press) Structural modification of receptor-binding technetium-99m complexes in order to improve brain uptake. Eur. J. Nucl. Med.
38. 2A serotonin receptor binding: Structure-affinity considerations. Nucl. Med. Biol. 23, 429-438.
39. John C. S., Lim B. B., Geyer B. C., Vilner B. J. and Bowen W. D. (in press) Tc-99m labeled sigma receptor-binding complex: Synthesis, characterization and specific binding to human ductal breast carcinoma (T47D) cells. Bioconjug. Chem.
40. Jurisson S. S., Pirro J., DiRocco R. J., Rosenspire K. C., Jagoda E., Nanjappan P. et al. (1995) Boronic acid adducts of technetium dioxime (BATO) complexes derived from quinuclidine benzilate (QNB) boronic acid stereoisomers: Syntheses and studies of their binding to the muscarinic acetylcholine receptor. Nucl. Med. Biol. 22, 269-281.
41. Katzenellenbogen J. A., Heiman D. F., Carlson K. E. and Lloyd J. E. (1982) In vivo and in vitro steroid receptor assays in the design of estrogen radiopharmaceuticals. In: Receptor-Binding Radiotracers (Edited by Eckelman W. C.), Vol. 1, pp. 93-126. CRC Press, Boca Raton, FL.
42. Kitayama S., Shimada S., Xu H., Markham L., Donovan D. M. and Uhl G. R. (1992) Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA 89, 7782-7785.
43. Kudo M., Vera D. R. and Stadalnik R. C. (1994) In vivo quantification of asialoglycoprotein receptor. Methods Enzymol. 247, 373-382.
44. 123]iodobenzovesamicol (IBVM). J. Nucl. Med. 34, 25P-26P.
45. Kung H. F. (1990) Radiopharmaceuticals for CNS receptor imaging with SPECT. Nucl. Med. Biol. 17, 85-92.
46. Kung H. F. (1996) The development of radiopharmaceuticals for imaging CNS receptors. In: Current Directions in Radiopharmaceutical Research and Development (Edited by Mather S. J.), pp. 99-113. Kluwer Academic, Dordecht, The Netherlands.
47. 1A receptor imaging agents. In: Technetium and Rhenium in Chemistry and Nuclear Medicine (Edited by Nicolini M., Bandoli G. and Mazzi U.), Vol. 4, pp. 293-298. SGEditoriali, Padua, Italy.
48. Kung H. F., Kim H.-J., Kung M.-P., Meegalla S. K., Plössl K. and Lee H.-K. (1996) Imaging of dopamine transporters in humans with Tc-99m TRODAT-1. Eur. J. Nucl. Med. 23, 1527-1530.
49. 99mTc]TRODAT-1: A novel Tc-99m complex as a dopamine transporter imaging agent. Eur. J. Nucl. Med.
50. Kurtaran A., Li S. R., Raderer M., Leimer M., Muller C., Pidlich J. et al. (1995) Technetium-99m-galactosyl-neoglycoalbumin combined with iodine-123-Tyr-(A14)-insulin visualizes human hepatocellular carcinomas. J. Nucl. Med. 36, 1875-1881.
51. Lastoria S., Vergara E., Varrella P., Muto P., Acampa W., Caraco C. et al. (1995) Imaging of thromboembolism by scintigraphy with the 99m-technetium-labelled synthetic peptide P280. Radiol. Med. (Torino) 90, 812-819.
52. Lever S. Z., Baidoo K. E., Mahmood A., Matsumura K., Scheffel U. and Wagner H. N., Jr. (1994) Novel technetium ligands with affinity for the muscarinic cholinergic receptor. Nucl. Med. Biol. 21, 157-164.
53. Lewin A. H., Gao Y., Abraham P., Boja J. W., Kuhar J. J. and Carroll F. I. (1992) 2β-Substituted analogues of cocaine: Synthesis and inhibition of binding to the cocaine receptor. J. Med. Chem. 35, 135-140.
54. 2 receptors. Life Sci. 28, 1015-1022.
55. 99mTc. Q. J. Nucl. Med. 40, 221-233.
56. Liu S., Edwards D. S., Looby R. J., Harris A. R., Poirier M. J., Barrett J. A. et al. (1996) Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with Tc-99m using aminocarboxylates as coligands. Bioconjug. Chem. 7, 63-71.
57. 99mTc]chelator-peptide conjugates. Bioconjug. Chem. 7, 196-202.
58. 18F]PNBS) in rats. Nucl. Med. Biol. 20, 269-278.
59. Macke H. R., Smith-Jones P., Maina T., Stolz B., Albert R., Bruns C. et al. (1993) New octreotide derivatives for in vivo targeting of somatostatin receptor-positive tumors for single photon emission computed tomography (SPECT) and positron emission tomography (PET). Horm. Metab. Res. Suppl. 21, 12-17.
60. 99mTechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 22, 239-246.
61. Maina T., Stolz B., Albert R., Bruns C., Koch P. and Macke H. (1994) Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labelled with technetium-99m. Eur. J. Nucl. Med. 21, 437-444.
62. McCarthy T. J., Schwarz S. W. and Welch M. J. (1994) Nuclear medicine and positron emission tomography: An overview. J. Chem. Ed. 71, 830-836.
63. Meegalla S., Plössl K., Kung M.-P., Chumpradit S., Stevenson D. A., Frederick D. et al. (1996) Tc-99m-labeled tropanes as dopamine transporter imaging agents. Bioconjug. Chem. 7, 421-429.
64. 99mTc complex as a dopamine transporter imaging agent. J. Am. Chem. Soc. 117, 11037-11038.
65. Meegalla S. K., Plössl K., Kung M.-P., Chumpradit S., Stevenson D. A., Kushner S. A. et al. (1997) Synthesis and characterization of Tc-99m-labeled tropanes (TRODAT) as dopamine transporter imaging agents. J. Med. Chem. 40, 9-17.
66. Mintun M. A., Welch M. J., Siegel B. A., Mathias C. J., Brodack J. W., McGuire A. H. et al. (1988) Breast cancer: PET imaging of estrogen receptors. Radiology 169, 45-48.
67. Muto P., Lastoria S., Varrella P., Vergara E., Salvatore M., Morgano G. et al. (1995) Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. J. Nucl. Med. 36, 1384-1391.
68. 2-metal conjugate. Bioconjug. Chem. 5, 182-193.
69. O'Neil J. P., Wilson S. R. and Katzenellenbogen J. A. (1994) Preparation and structural characterization of monoamine-monoamide bis(thiol) oxo complexes of technetium(V) and rhenium(V). Inorg. Chem. 33, 319-323.
70. Ojima I., Chakravarty S. and Dong Q. (1995) Antithrombotic agents: From RGD to peptide mimetics. Bioorg. Med. Chem. 3, 337-360.
71. 1A receptor imaging agents. J. Nucl. Med. 37, 190P.
72. 99mTc-labelled aminothiols. Nucl. Med. Biol. 20, 101-104.
73. Parker M. G. (1991) Nuclear Hormone Receptors. Academic Press, London.
74. Pearson D. A., Lister-James J., McBride W. J., Wilson D. M., Martel L. J., Civitello E. R. et al. (1996) Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists: Chemistry and initial biological studies. J. Med. Chem. 39, 1372-1382.
75. Pearson D. A., Lister-James J., McBride W. J., Wilson D. M., Martel L. J., Civitello E. R. et al. (1996) Somatostatin receptor-binding peptides labeled with technetium-99m: Chemistry and initial biological studies. J. Med. Chem. 39, 1361-1371.
76. Piwnica-Worms D., Chiu M. L., Budding M., Kronauge J. F., Kramer R. A. and Croop J. M. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53, 977-984.
77. 99mTc-labeled chemotactic peptides: Analogues with reduced neutropenia. Nucl. Med. Commun. 17, 132-139.
78. Rajopadhye M., Edwards D. S., Bourque J. P. and Carroll T. R. (1996) Synthesis and technetium-99m labeling of cyclic GP IIB/IIIA receptor antagonists conjugated to 4,5-bis(mercaptoacetamido)-pentanoic acid (MAPT). Bioorg. Med. Chem. Lett. 6, 1737-1740.
79. Reizer J., Reizer A. and Saier M. H., Jr. (1994) A functional super-family of sodium/solute symporters. Biochim. Biophys. Acta 1197, 133-166.
80. Renaud J.-P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H. et al. (1995) Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid. Nature 378, 681-689.
81. 99mTc-labelling of proteins and peptides: Factors that alter radiochemical yields and in vivo stability. In: Technetium and Rhenium in Chemistry and Nuclear Medicine (Edited by Nicolini M., Bandoli G. and Mazzi U.), Vol. 4, pp. 281-286. SGEditoriali, Padua, Italy.
82. Rzeszotarski W. J., Gibson R. E., Eckelman W. C., Simms D. A., Jagoda E. M., Ferreira N. L. et al. (1982) Analogues of 3-quinuclidinyl benzilate. J. Med. Chem. 25, 1103-1106.
83. 99mTc-bisaminoethanethiol spiperone derivatives: Possible ligands for receptor imaging with SPECT. Nucl. Med. Biol. 22, 573-583.
84. Schwartz T. W. (1996) Molecular structure of G-protein coupled receptors. In: Textbook of Receptor Pharmacology (Edited by Foreman J. C. and Johansen T.), pp. 65-84. CRC Press, Boca Raton, FL.
85. Schwochau K. (1994) Technetium radiopharmaceuticals - fundamentals, synthesis, structure, and development. Angew. Chem. Int. Ed. Engl. 33, 2258-2267.
86. Spies H. and Johannsen B. (1995) Functionalization of technetium complexes to make them active in vivo. Analyst 120, 775-777.
87. Spies H., Noll B., Noll S., Findeisen M., Leibnitz P., Schulze P. E. et al. (in press) Synthesis and molecular structure of a rhenium complex derived from 6-methyl-8α-aminoergoline. Chem. Ber.
88. Spradau T. W. and Katzenellenbogen J. A. (1994) Unpublished results [non-steroidal estrogens linked to cyclopentadienyl tricarbonyl rhenium].
89. Stadalnik R. C., Vera D. R., Woodle E. S., Trudeau W. L., Porter B. A., Ward R. E. et al. (1985) Technetium-99m NGA functional hepatic imaging: Preliminary clinical experience. J. Nucl. Med. 26, 1233-1242.
90. Su T. P. (1993) Delineating biochemical and functional properties of sigma receptors: Emerging concepts. Crit. Rev. Neurobiol. 7, 187-203.
91. Sugano Y. and Katzenellenbogen J. A. (1996) Synthesis of tetradentate bisamino-bisthiol complexes of oxorhenium(V) as structural mimics of steroids. Bioorg. Med. Chem. Lett. 6, 361-366.
92. Tamagan G., Gao Y., Baldwin R. M., Zoghbi S. S. and Neumeyer J. L. (1996) Synthesis of β-CIT-BAT, a potential technetium-99m imaging ligand for dopamine transporter. Tetrahedron Lett. 37, 4353-4356.
93. Tatsch K., Schwarz J., Oertel W. H. and Kirsch C.-M. (1992) Dopamine D2 receptor imaging with I-123 IBZM SPECT to differentiate idiopathic from other Parkinson syndromes. J. Nucl. Med. 33, 917P-918P.
94. 3 kit formulation: Preliminary results in normal volunteers and patients with renal failure. J. Nucl. Med. 29, 616-622.
95. 3 renal imaging in volunteers. J. Nucl. Med. 27, 795-803.
96. Top S., El Hafa H., Vessières A., Quivy J., Vaissermann J., Hughes D. W. et al. (1995) Rhenium carbonyl complexes of β-estradiol derivatives with high affinity for the estradiol receptor: An approach to selective organometallic radiopharmaceuticals. J. Am. Chem. Soc. 117, 8372-8380.
97. Top S., Vessières A. and Jaouen G. (1994) Synthetic strategy for organometallic complexes of rhenium with exceptionally high affinity for the oestradiol receptor; their potential use as imaging and therapeutic agents. J. Chem. Soc., Chem. Commun., 453-454.
98. Vallabhajosula S., Moyer B. R., Lister-James J., McBride B. J., Lipszyc H., Lee H. et al. (1996) Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J. Nucl. Med. 37, 1016-1022.
99. 18F]Fluoro)estrogens: Systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J. Med. Chem. 36, 1619-1629.
100. Varnum J. M., Thakur M., Mayo K. H. and Jansen S. A. (1996) Stability and conformational analysis of Tc-RC160 and Re-RC160: Experimental and theoretical analysis of the influence of metal complexation on the structural requisites for activity. J. Phys. Chem. 100, 14630-14636.
101. 1H NMR and computer modeling conformational analysis. J. Biol. Chem. 269, 12583-12588.
102. Vera D. R., Krohn K. A., Stadalnik R. C. and Scheibe P. O. (1984) Tc-99m galactosyl-neoglycoalbumin: In vitro characterization of receptor-mediated binding. J. Nucl. Med. 25, 779-787.
103. Vera D. R., Krohn K. A., Stadalnik R. C. and Scheibe P. O. (1984) Tc-99m-galactosyl-neoglycoalbumin: In vivo characterization of receptor-mediated binding to hepatocytes. Radiology 151, 191-196.
104. Vera D. R., Stadalnik R. C. and Krohn K. A. (1985) Technetium-99m galactosyl-neoglycoalbumin: Preparation and preclinical studies. J. Nucl. Med. 26, 1157-1167.
105. Vera D. R., Stadalnik R. C., Kudo M. and Krohn K. A. (1994) Radiopharmaceutical preparation of technetium-99m-labeled galactosyl neoglycoalbumin. Methods Enzymol. 247, 402-409.
106. Vera D. R., Stadalnik R. C., Metz C. E. and Pimstone N. R. (1996) Diagnostic performance of a receptor-binding radiopharmacokinetic model. J. Nucl. Med. 37, 160-164.
107. Vera D. R., Stadalnik R. C., Trudeau W. L., Scheibe P. O. and Krohn K. A. (1991) Measurement of receptor concentration and forward-binding rate constant via radiopharmacokinetic modeling of technetium-99m-galactosyl-neoglycoalbumin. J. Nucl. Med. 32, 1169-1176.
108. Vera D. R., Wisner E. R. and Stadalnik R. C. (in press) Sentinel node imaging via a nonparituclate receptor-binding radiotracer. J. Nucl. Med.
109. Verbruggen A. M. (1990) Radiopharmaceuticals: State of the art. Eur. J. Nucl. Med. 17, 346-364.
110. Volkow N. D., Fowler J. S., Wang G.-J., Dewey S. L., Schlyer D., MacGregor R. et al. (1993) Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J. Nucl. Med. 34, 609-613.
111. Wagner R. L., Apriletti J. W., McGrath M. E., West B. L., Baxter J. D. and Fletterick R. J. (1995) A structural role for hormone in the thyroid hormone receptor. Nature 378, 690-697.
112. Walovitch R. C., Williams S. J. and Lafrance N. D. (1990) Radiolabeled agents for SPECT imaging of brain perfusion. Nucl. Med. Biol. 17, 77-83.
113. Wentworth P., Jr., Wiemann T. and Janda K. D. (1996) A new class of pentacoordinate ribonuclease inhibitors: Synthesis, characterization, and inhibition studies of ribonucleoside and anhydropentofuranose oxorhenium(V) complexes. J. Am. Chem. Soc. 118, 12521-12527.
114. Wurtz J.-M., Bourguet W., Renaud J.-P., Vivat V., Chambon P., Moras D. et al. (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol. 3, 87-94.
115. Wüst F., Spies H. and Johannsen B. (1996) Synthesis of "3 + 1" mixed-ligand oxorhenium(V) complexes containing modified 3,17β-estradiol. Bioorg. Med. Chem. Lett. 6, 2729-2734.
116. Zoghbi S. S., Tamagnan G., Baldwin R. M., Gao Y., Neumeyer J. L., Baldessarini R. et al. (in press) Synthesis of a dopamine transporter binding cyclopentadiene phenyltropane conjugate complexed with Re and Tc-99m [abstract]. J. Nucl. Med.